Answers are grounded in this paper and cite their sources.
0.0014% of dose) and 73.5% direct transport percentage (DTP), accompanied by markedly reduced plasma and liver exposure. Pharmacodynamic evaluation confirmed sustained activation of RXR-responsive genes, including SCD1 and LXRα, following intranasal nanoparticle delivery. These findings demonstrate that optimized GPNPs enable efficient CNS targeting and support their use as a promising intranasal platform for delivery of RXR agonists and other hydrophobic therapeutics.
No takes yet. Share an insight, caveat, or question.
Hakim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: